Actualités

Healthcare stocks rose Monday afternoon, with the NYSE Healthcare Index adding 0.4% and the State St

Eli Lilly (NYSE:LLY) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion. But here’s what you should actually be watching. The ... Three Biotechs That Are Top Takeover Targets

Strong drug sales continue to drive growth, but expectations are climbing

Baxfendy gained FDA clearance for uncontrolled hypertension patients as AstraZeneca expands its cardiovascular and metabolic portfolio.

Drugmaker sees international markets as next test for obesity pill demand.

Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline in prescriptions, according to Citi's latest tracking data. The bank's weekly prescription tracker, based on IQVIA data, showed Wegovy...

As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly.

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Eli Lilly recently reported detailed late-phase trial results showing that people with obesity were able to maintain long-term weight loss after switching to oral Foundayo or lower-dose Zepbound, while also committing an additional US$4.50 billion to expand its Indiana manufacturing network for obesity and genetic medicines. The combination of durable weight maintenance data for Foundayo and Zepbound and large-scale production expansion underscores how central obesity treatments have become...

Eli Lilly and Company (NYSE:LLY) is among the stocks with the best earnings growth for the next 10 years. On May 5, Emily Field from Barclays lifted the price target on Eli Lilly and Company (NYSE:LLY) to $1,400 from $1,350 and maintained an Overweight rating following the first-quarter results. In a research note, the analyst […]

There's a new challenger to the more established players in the weight-loss drug space.

Eli Lilly and Company (NYSE:LLY) is one of the Top 10 Stocks That Will Profit from AI. The company has recently introduced LillyPod, the pharmaceutical industry’s most powerful NVIDIA-powered supercomputer. Embedded with AI, Lillypod is part of a continuous learning system that accelerates drug discovery and development. On May 12, 2026, Eli Lilly and Company […]

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.4% in the afternoon session after the stock continued to rally as the company announced an additional $4.5 billion investment to expand its U.S. manufacturing capabilities as it prepares for surging demand for its weight-loss medications.

Picture a drug so popular that, even in markets where a cheaper generic competitor had just launched, it still grew by 10%. That's what happened to Eli Lilly's (LLY) Mounjaro in India recently. And it's the kind of detail that makes Morgan Stanley think Wall Street still isn't giving Lilly's ...

Eli Lilly (LLY) stock is back in focus after the company reported a very strong Q1, raised its full year revenue and earnings guidance, and released new obesity trial data on Foundayo and Zepbound. See our latest analysis for Eli Lilly. The recent obesity trial updates, expanded manufacturing plans and steady flow of product news have kept Eli Lilly in the spotlight. A 30 day share price return of 9.13% has helped the stock recover some ground after a year to date decline of 6.82%. The 1 year...

Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.

ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.

Lance Roberts of RIA Advisors warned on the Thoughtful Money podcast that the S&P 500 has stretched so far above its key moving averages that a mean-reversion move could be a higher-probability scenario heading into the summer. “The big risk here is right now… we’ve got this massive deviation that’s going on kind of in ... Prediction. The S&P 500 Is So Far Above Its Moving Averages That a 10% Correction This Summer Is Not Out of the Question

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Eli Lilly and Company (NYSE:LLY) is included among the 10 Best US Stocks to Invest in According to Billionaires. Eli Lilly and Company (NYSE:LLY) discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. On May 8, Guggenheim analyst Seamus Fernandez boosted the firm’s price target on Eli Lilly […]

Eli Lilly (NYSE:LLY) announced a $50 million partnership with UNICEF USA tied to its 150th anniversary. The multi-year program targets childhood non-communicable diseases across 21 low and middle income countries. The company is also supporting large scale food distribution and infrastructure projects in the US. Eli Lilly is bringing its ESG profile into sharper focus with this UNICEF USA partnership, which centers on expanding primary care capacity for conditions like childhood diabetes...

By Daniella Parra Imviva Biotech said data showed its CTA313 drug resulted in 50% of patients going into remission for systemic lupus. Many patients experience incomplete responses, recurrent flares and long-term treatment-related toxicity, it said. “The clinical activity observed with CTA313 in systemic lupus erythematosus is highly encouraging, with 100% of patients achieving an SRI-4 […]

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

Eli Lilly (NYSE:LLY) just delivered one of the most impressive quarters in big pharma history, and the stock is responding. After a sharp drawdown in early 2026, shares have rebounded 9.27% over the past month as Mounjaro and Zepbound continue to redefine the obesity and diabetes treatment landscape. Our 24/7 Wall St. price target points ... Is Eli Lilly Going To $1,100?

Eli Lilly and Company (NYSE:LLY) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. During the lightning round, a caller inquired about the stock, and Cramer replied: Eli Lilly, I did a tremendous amount of work on Eli Lilly. I was […]

NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.

Pfizer stock slipped after Q1 results despite an earnings beat as investors weighed falling COVID sales and looming patent expirations.

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

Is LLY a good stock to buy? We came across a bullish thesis on Eli Lilly and Company on Value & Momentum Portfolio’s Substack. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $987.05 as of May 6th. LLY’s trailing and forward P/E were 35.13 and 28.82 […]